Humacyte Stock Total Debt
| HUMAW Stock | USD 1.50 0.09 5.66% |
Humacyte fundamentals help investors to digest information that contributes to Humacyte's financial success or failures. It also enables traders to predict the movement of Humacyte Stock. The fundamental analysis module provides a way to measure Humacyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Humacyte stock.
Total Debt To Capitalization is likely to climb to 0.79 in 2024. Humacyte | Total Debt |
Humacyte Company Total Debt Analysis
Humacyte's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Humacyte Total Debt | 58.11 M |
Most of Humacyte's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Humacyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Humacyte Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Humacyte is extremely important. It helps to project a fair market value of Humacyte Stock properly, considering its historical fundamentals such as Total Debt. Since Humacyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Humacyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Humacyte's interrelated accounts and indicators.
Click cells to compare fundamentals
Humacyte Total Debt Historical Pattern
Today, most investors in Humacyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Humacyte's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Humacyte total debt as a starting point in their analysis.
Humacyte Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Humacyte Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Humacyte has a Total Debt of 58.11 M. This is 97.89% lower than that of the Biotechnology sector and 82.11% lower than that of the Health Care industry. The total debt for all United States stocks is 98.91% higher than that of the company.
Humacyte Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Humacyte's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics of similar companies.Humacyte is currently under evaluation in total debt category among its peers.
Humacyte Fundamentals
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Total Debt | 58.11 M | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Earnings Per Share | (3.16) X | ||||
| Number Of Employees | 183 | ||||
| Beta | 1.47 | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
| Net Asset | 128.22 M |
About Humacyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.